share_log

Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor

Glucotrack Announces Increased Sensor Longevity For Its Implantable Continuous Blood Glucose Monitor

Glucotrack 宣佈延長其植入式連續血糖監測器的傳感器壽命
Benzinga ·  04/02 20:35

Computational modeling with The Technology Partnership shows sensor longevity beyond 3 years; 1 year longer than previously announced

與技術合作夥伴關係進行的計算建模顯示,傳感器的使用壽命超過3年;比之前宣佈的壽命延長了1年

Implantable Continuous Blood Glucose Monitor technology could transform lives of patients with diabetes

植入式連續血糖監測器技術可以改變糖尿病患者的生活

Rutherford, NJ & Cambridge, UK, April 02, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, and The Technology Partnership ("TTP"), today announced the completion of computational modeling for Glucotrack's implantable Continuous Blood Glucose Monitor ("CBGM"), suggesting sensor longevity beyond three years, a year longer than the Company previously announced.

新澤西州盧瑟福和英國劍橋,2024年4月2日(GLOBE NEWSWIRE)——專注於糖尿病患者新技術設計、開發和商業化的醫療器械公司Glucotrack, Inc.(納斯達克股票代碼:GCTK)(“Glucotrack” 或 “公司”)以及技術夥伴關係(“TTP”)今天宣佈完成Glucotrack的計算建模植入式連續血糖監測儀(“CBGM”),表明傳感器的使用壽命超過三年,比該公司先前宣佈的長一年。

Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. This in silico modeling specifically evaluated the expected longevity of the Glucotrack CBGM sensor implementation. The CBGM sensor leverages well-established cardiovascular technology to directly measure blood glucose intravenously, providing more rapid glucose monitoring results without the 15-20-minute lag seen with interstitial glucose sensors.

Glucotrack已聘請TTP開發計算建模,該建模可以解決長期植入式電化學傳感器中使用的酶壽命問題。這個 在計算機中 建模專門評估了實施Glucotrack CBGM傳感器的預期壽命。CBGM 傳感器利用成熟的心血管技術,通過靜脈注射直接測量血糖,提供更快的血糖監測結果,而不會出現間質葡萄糖傳感器出現的 15-20 分鐘延遲。

Previously, Glucotrack had announced a projected sensor longevity of 2+ years. TTP's modeling confirmed the 2+ year projection, but TTP's modeling further projects that the Glucotrack CBGM sensor longevity may now be capable of reaching 3+ years. The model developed by TTP captures numerous processes and complex aspects of the sensor function, including the rate of glucose transport in typical in-vivo conditions, the consumption of enzyme, and the impact of reaction components while incorporating appropriate benchtop sensor data.

此前,Glucotrack曾宣佈傳感器的預計使用壽命爲2年以上。TTP的建模證實了2年以上的預測,但TTP的建模進一步預測,Glucotrack CBGM傳感器的使用壽命現在可能達到3年以上。TTP 開發的模型捕捉了傳感器功能的衆多過程和複雜方面,包括典型的葡萄糖轉運速率 活體 條件、酶消耗以及反應成分的影響,同時納入適當的臺式傳感器數據。

TTP brings over 35 years of experience in the life science and healthcare sectors to this project, with specific expertise in multiphysics modeling, electrochemical sensor development, and the design and integration of wearable and implantable medical devices. TTP's knowledge and skills have been instrumental in evaluating and extending the projected longevity of the Glucotrack CBGM sensor.

TTP 爲該項目帶來了生命科學和醫療保健領域超過 35 年的經驗,在多物理場建模、電化學傳感器開發以及可穿戴和植入式醫療設備的設計和集成方面擁有專業知識。TTP的知識和技能在評估和延長Glucotrack CBGM傳感器的預計壽命方面發揮了重要作用。

"TTP is well versed in supporting clients with creating breakthrough medical technology solutions," said Paul Goode, PhD, CEO of Glucotrack. "This collaboration has enhanced our development program, and the projected increase in sensor longevity to beyond three years further demonstrates that our technology is truly differentiated in the glucose monitoring space. This achievement doesn't change our commercialization timing but instead paves the way for future generations of our system, which will be a truly long-term CBGM to people living every day with diabetes."

Glucotrack首席執行官保羅·古德博士表示:“TTP精通支持客戶創建突破性的醫療技術解決方案。”“這種合作加強了我們的開發計劃,預計傳感器的使用壽命將延長至三年以上,這進一步表明我們的技術在葡萄糖監測領域確實與衆不同。這一成就並沒有改變我們的商業化時機,而是爲我們系統的子孫後代鋪平了道路,對於每天生活在糖尿病患者來說,這將是真正的長期CBGM。”

Chris Dawson, PhD, Head of Biosensing at TTP, said: "We are delighted to be working on this exciting and disruptive technology with Glucotrack. These tremendously promising results, coupled with Glucotrack's innovative approach to glucose monitoring, means that this technology has the potential to deliver a new way for patients to manage their diabetes with discretion and minimal disruption to their lives."
For more information about Glucotrack's CBGM, visit glucotrack.com.

TTP生物傳感負責人克里斯·道森博士表示:“我們很高興與Glucotrack合作開發這項令人興奮的顛覆性技術。這些非常有希望的結果,加上Glucotrack創新的血糖監測方法,意味着這項技術有可能爲患者提供一種全新的方式,使他們能夠謹慎地管理糖尿病,最大限度地減少對生活的干擾。”
有關 Glucotrack CBGM 的更多信息,請訪問 glucotrack.com。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論